Breaking News

Baxter to Acquire Chatham Therapeutics

April 2, 2014

Gains gene therapy programs for hemophilia treatments

Baxter International Inc. has entered an agreement to acquire Chatham Therapeutics for an initial payment of $70 million, and potential future payments based on certain development, regulatory and commercial milestones. With the acquisition, Baxter gains Chatham’s developmental gene therapy programs for the development and commercialization of treatments for hemophilia.
 
The two companies entered a collaboration in May 2012 to evaluate Chatham’s Biological Nano Particle (BNP) platform for potential treatments for hemophilia B, resulting in BAX 335, which is currently in Phase I/II development. Baxter will also have access to the previously partnered hemophilia B (FIX) program, a preclinical hemophilia A (FVIII) program, and the potential future application to additional hemophilia treatments.
 
''Chatham’s gene therapy platform technology offers the potential to redefine treatment of both hemophilia A and B,'' said Ludwig Hantson, Ph.D., president of Baxter BioScience. ''This technology will be highly complementary to our expanding pipeline of bleeding disorder treatments as we continue our pursuit of a bleed-free world.''
 
''Given Baxter’s long-standing commitment to innovative product development in hemophilia, we are confident that this transaction provides the best opportunity for the advancement of our BNP gene therapy platform technology for the benefit of hemophilia patients worldwide. The integration of Chatham’s next-generation technology and expertise, along with Baxter’s global marketing and distribution presence, is a combination we anticipate will support efficient delivery of a potential new class of therapeutics to the hemophilia market,'' said Jade Samulski, co-founder of Chatham and vice president of Asklepios BioPharmaceutical, Inc.
 
Following the acquisition, Chatham will maintain its licensing and development relationship with Asklepios BioPharmaceutical on the development of novel hemophilia therapeutic gene therapy candidates using the BNP platform.

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important